We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

12 hedge funds and large institutions have $6.96M invested in AYTU BioPharma in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $6.04M → $6.96M (+$919K)

0.07% more ownership

Funds ownership: 0.1% → 0.16% (+0.07%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

8% less funds holding

Funds holding: 13 → 12 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

Holders
12
Holders Change
-1
Holders Change %
-7.69%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$4.7M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$73.2K
3
SC
Searle & Co
Connecticut
+$73.2K
4
VF
Virtu Financial
New York
+$44.9K
5
Citadel Advisors
Citadel Advisors
Florida
+$19.3K

Top Sellers

Rank Fund Capital Flow
1
WC
Wexford Capital
Florida
-$912K
2
Bank of New York Mellon
Bank of New York Mellon
New York
-$75K
3
Bank of America
Bank of America
North Carolina
-$44.3K
4
ARTA
A.R.T. Advisors
New York
-$23K
5
JP Morgan Chase
JP Morgan Chase
New York
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$6.2M +$4.7M +15,600 +156%
SC
2
Searle & Co
Connecticut
$302K +$73.2K +243 +24%
WC
3
Wexford Capital
Florida
$123K -$912K -3,030 -86%
Vanguard Group
4
Vanguard Group
Pennsylvania
$115K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$79K – – –
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$58K +$73.2K +243 New
VF
7
Virtu Financial
New York
$36K +$44.9K +149 New
BlackRock
8
BlackRock
New York
$22K -$1.5K -5 -5%
Citadel Advisors
9
Citadel Advisors
Florida
$15K +$19.3K +64 New
Northern Trust
10
Northern Trust
Illinois
$13K – – –
Victory Capital Management
11
Victory Capital Management
Texas
$4K +$4.52K +15 New
Bank of New York Mellon
12
Bank of New York Mellon
New York
– -$75K -199 Closed
Bank of America
13
Bank of America
North Carolina
– -$44.3K -147 Closed
JP Morgan Chase
14
JP Morgan Chase
New York
– -$22K -62 Closed
ARTA
15
A.R.T. Advisors
New York
– -$23K -61 Closed
UBS Group
16
UBS Group
Switzerland
– -$6.62K -22 Closed
TRCT
17
Tower Research Capital (TRC)
New York
– -$2K -4 Closed
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
– +$301 +1 New

AYTU Hedge Fund Activity: Q3 2019 in Review

12 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2019, worth a combined $6.96M — up 15% from $6.04M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of AYTU and 5 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was Armistice Capital, adding an estimated $4.7M. The largest seller was Wexford Capital, cutting an estimated $912K.

  • 12 institutional investors held AYTU BioPharma (AYTU) as of Q3 2019, down from 13 in Q2 2019.
  • Funds reported $6.96M of AYTU BioPharma stock for Q3 2019, up 15% quarter-over-quarter.
  • 5 funds opened new AYTU BioPharma positions in Q3 2019 and 6 closed out, a net change of -1 holder.
  • The largest AYTU BioPharma buyer in Q3 2019 was Armistice Capital, an estimated $4.7M added.
  • The largest AYTU BioPharma seller in Q3 2019 was Wexford Capital, an estimated $912K sold.

Based on aggregated 13F filings for Q3 2019.